PFIZER INC

PFE 10-K · Q4 2025
API behind this page

PFE Q4 2025 request

Playground key active
Request URL /api/financials?ticker=PFE&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue (Q) — — —
Show Product Lines breakouts
Product 14,495 15,085 -3.9%
Royalty 480 431 +11.4%
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer 2,582 2,248 +14.9%
Show Product Lines breakouts
Total Alliance revenues [Member] 2,582 2,248 +14.9%
Revenue 17,557 17,763 -1.2%
Show Product Lines breakouts
Abrysvo [Member] · Biopharma [Member] 480 198 +142.4%
Adcetris [Member] · Biopharma [Member] 220 285 -22.8%
All other Hospital [Member] · Biopharma [Member] 1,059 1,085 -2.4%
All other Oncology [Member] · Biopharma [Member] 303 285 +6.3%
All other Primary Care [Member] · Biopharma [Member] 789 787 +0.3%
All other Specialty Care [Member] · Biopharma [Member] 476 344 +38.4%
Aromasin [Member] · Biopharma [Member] 117 90 +30.0%
Bosulif [Member] · Biopharma [Member] 161 171 -5.8%
Braftovi/Mektovi [Member] · Biopharma [Member] 197 170 +15.9%
Cibinqo [Member] · Biopharma [Member] 78 63 +23.8%
Comirnaty [Member] · Biopharma [Member] 2,270 3,383 -32.9%
Cresemba [Member] · Biopharma [Member] 82 68 +20.6%
Eliquis [Member] · Biopharma [Member] 2,020 1,832 +10.3%
Elrexfio [Member] · Biopharma [Member] 74 57 +29.8%
Enbrel (Outside the U.S. and Canada) [Member] · Biopharma [Member] 179 183 -2.2%
FSME-IMMUN/TicoVac [Member] · Biopharma [Member] 47 34 +38.2%
Genotropin [Member] · Biopharma [Member] 117 112 +4.5%
Ibrance [Member] · Biopharma [Member] 1,039 1,095 -5.1%
Inlyta [Member] · Biopharma [Member] 235 242 -2.9%
Lorbrena [Member] · Biopharma [Member] 282 193 +46.1%
Nurtec ODT/Vydura [Member] · Biopharma [Member] 405 393 +3.1%
Octagam [Member] · Biopharma [Member] 120 109 +10.1%
Oncology Biosimilars [Member] · Biopharma [Member] 369 209 +76.6%
Orgovyx [Member] · Biopharma [Member] 136 65 +109.2%
Padcev [Member] · Biopharma [Member] 508 444 +14.4%
Pfizer CentreOne [Member] 409 326 +25.5%
Pfizer Ignite [Member] 4 26 -84.6%
Prevnar Family [Member] · Biopharma [Member] 1,708 1,558 +9.6%
Sulperazon (Outside the U.S. and Canada) [Member] · Biopharma [Member] 169 169 0.0%
Talzenna [Member] · Biopharma [Member] 49 26 +88.5%
Tivdak [Member] · Biopharma [Member] 32 37 -13.5%
Tukysa [Member] · Biopharma [Member] 119 129 -7.8%
Vyndaqel Family [Member] · Biopharma [Member] 1,688 1,544 +9.3%
Xeljanz [Member] · Biopharma [Member] 324 350 -7.4%
Xtandi [Member] · Biopharma [Member] 592 565 +4.8%
Zavicefta (Outside the U.S. and Canada) [Member] · Biopharma [Member] 181 159 +13.8%
Zithromax [Member] · Biopharma [Member] 113 123 -8.1%
Show Business Segments breakouts
Biopharma [Member] 17,143 17,413 -1.6%
Biopharma [Member] · International Commercial Division 8,112 8,299 -2.3%
Biopharma [Member] · Oncology [Member] 4,435 4,063 +9.2%
Biopharma [Member] · Operating Segments 17,143 17,413 -1.6%
Biopharma [Member] · Primary Care [Member] 7,938 8,911 -10.9%
Biopharma [Member] · Specialty Care [Member] 4,771 4,437 +7.5%
Biopharma [Member] · U.S. Commercial Division 9,031 9,114 -0.9%
Show Geography breakouts
Developed Markets [Member] 5,921 6,283 -5.8%
Emerging Markets [Member] 2,517 2,259 +11.4%
US 9,119 9,221 -1.1%
Show — breakouts
Revenue 54,005 50,949 +6.0%
Revenue 181 127 +42.5%
Revenue 1,897 5,334 -64.4%
Show Consolidation Items breakouts
Corporate Non Segment 414 351 +17.9%
Cost of Revenue 5,272 5,909 -10.8%
Show Business Segments breakouts
Biopharma [Member] 4,590 5,313 -13.6%
Selling, General & Administrative 4,162 4,274 -2.6%
Show Business Segments breakouts
Biopharma [Member] 2,898 3,067 -5.5%
Research And Development Expense Excluding Acquired In Process Cost 3,206 3,035 +5.6%
Show Business Segments breakouts
Biopharma [Member] 2,948 2,733 +7.9%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 212 88 +140.9%
Show Business Segments breakouts
Biopharma [Member] 62 88 -29.5%
Amortization Of Intangible Assets Not Associated With Single Function 1,230 1,359 -9.5%
Restructuring Charges And Acquisition Related Costs 605 750 -19.3%
Other Non-Operating Income (Expense) 4,514 2,358 +91.4%
Show Business Segments breakouts
Biopharma [Member] -268 -51 -425.5%
Income Before Taxes -1,642 -10 -16320.0%
Show Business Segments breakouts
Biopharma [Member] 6,913 6,262 +10.4%
Biopharma [Member] · Operating Segments 6,913 6,262 +10.4%
Show Consolidation Items breakouts
Corporate Non Segment -1,969 -1,825 -7.9%
Material Reconciling Items · Acquisition-Related Items [Member] -471 -348 -35.3%
Material Reconciling Items · Amortization of Intangible Assets [Member] -1,230 -1,359 +9.5%
Material Reconciling Items · Certain Significant Items [Member] -4,886 -2,742 -78.2%
Income Tax Expense (Benefit) -2 -421 +99.5%
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest -1,640 411 -499.0%
Income Loss From Discontinued Operations Net Of Tax 0 7 -100.0%
Net Income -1,640 418 -492.3%
Show Equity Components breakouts
Noncontrolling Interest 8 8 0.0%
Parent -1,648 410 -502.0%
Retained Earnings -1,648 410 -502.0%
Net Income Loss Attributable To Noncontrolling Interest 8 8 0.0%
Net Income -1,648 410 -502.0%
Income Loss From Continuing Operations Per Basic Share -0.29 0.07 -514.3%
EPS (Basic) -0.29 0.07 -514.3%
Income Loss From Continuing Operations Per Diluted Share -0.29 0.07 -514.3%
EPS (Diluted) -0.29 0.07 -514.3%
Wtd Avg Shares (Basic) 1 1 0.0%
Wtd Avg Shares (Diluted) 3 1 +200.0%
Interest Income -166 -171 +2.9%
Comprehensive Income -1,651 538 -406.9%
Net Income Loss Available To Common Stockholders Basic -1,648 410 -502.0%
Interest Expense 711 739 -3.8%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash & Cash Equivalents 1,142 1,043 +9.5%
Accounts Receivable 11,874 11,463 +3.6%
Inventory 10,654 10,851 -1.8%
Other Tax Assets Current 3,967 3,314 +19.7%
Other Assets Current 2,808 4,253 -34.0%
Total Current Assets 42,898 50,358 -14.8%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 4,991 4,338 +15.1%
Non-Current Assets
Property, Plant & Equipment 19,317 18,393 +5.0%
Show Geography breakouts
Developed Markets [Member] 8,180 7,187 +13.8%
Emerging Markets [Member] 1,457 1,458 -0.1%
US 9,680 9,748 -0.7%
Goodwill 71,264 68,527 +4.0%
Deferred Tax Assets Net And Other Tax Assets Noncurrent 9,699 8,662 +12.0%
Other Non-Current Assets 9,631 9,817 -1.9%
Total Assets 208,160 213,396 -2.5%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 8,288 7,561 +9.6%
Operating Lease Right-of-Use Assets 2,213 2,289 -3.3%
Intangible Assets 31,510 35,848 -12.1%
Show Finite Lived Intangible Assets By Major Class breakouts
Developed Technology Rights 30,458 34,353 -11.3%
Licensing Agreements and Other [Member] 1,052 1,210 -13.1%
Other Assets
Other Short Term Investments 12,454 19,434 -35.9%
Other Long Term Investments 1,621 2,228 -27.2%
Intangible Assets Net Excluding Goodwill 53,731 55,411 -3.0%
Current Liabilities
Debt Current 3,154 6,946 -54.6%
Accounts Payable 5,240 5,633 -7.0%
Dividends Payable Current 2,445 2,437 +0.3%
Taxes Payable Current 3,103 2,910 +6.6%
Employee Related Liabilities Current 3,610 3,838 -5.9%
Deferred Revenue (Current) 784 1,511 -48.1%
Show Product Lines breakouts
Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] 689 1.4 +49114.3%
Other Liabilities Current 18,648 19,720 -5.4%
Show Product Lines breakouts
Comirnaty [Member] · BioNTech [Member] 911 1.3 +69976.9%
Total Current Liabilities 36,984 42,995 -14.0%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 4,714 4,280 +10.1%
Current Portion of Long-Term Debt 2,997 3,747 -20.0%
Show Long-Term Debt Type breakouts
Unsecured Debt 2,997 3,747 -20.0%
Non-Current Liabilities
Long-Term Debt 61,641 57,405 +7.4%
Show Long-Term Debt Type breakouts
Unsecured Debt 61,641 57,405 +7.4%
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent 2,041 2,115 -3.5%
Show Retirement Plan Type breakouts
Other Postretirement Benefit Plans Defined Benefit 75 74 +1.4%
Pension Plans Defined Benefit · Foreign Plan 1,334 1,364 -2.2%
Pension Plans Defined Benefit · US 632 678 -6.8%
Deferred Tax Liabilities 2,401 2,122 +13.1%
Liability For Uncertain Tax Positions Noncurrent 3,591 6,112 -41.2%
Other Non-Current Liabilities 14,725 14,150 +4.1%
Total Liabilities 121,385 124,899 -2.8%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] 10,449 10,485 -0.3%
Long-Term Debt (Q) — — —
Show Derivative Risk breakouts
Foreign Currency Long-Term Debt [Member] 879 777 +13.1%
Operating Lease Liabilities 2,291 2,286 +0.2%
Contract With Customer Liability Noncurrent (Q) — — —
Show Product Lines breakouts
Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] 826 785 +5.2%
Other Liabilities
Minority Interest 299 294 +1.7%
Stockholders' Equity
Common Stock 481 480 +0.2%
Additional Paid-In Capital 94,469 93,603 +0.9%
Treasury Stock Common Value -115,015 -114,763 -0.2%
Retained Earnings 114,610 116,725 -1.8%
Accumulated Other Comprehensive Income -8,069 -7,842 -2.9%
Total Stockholders' Equity 86,476 88,203 -2.0%
Show Equity Method Investment Nonconsolidated Investee breakouts
ViiV [Member] -2,161 -2,924 +26.1%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 86,775 88,497 -1.9%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment Net Prior Service Cost Credit 75 191 -60.7%
Accumulated Gain Loss Net Cash Flow Hedge Parent -321 57 -663.2%
Accumulated Net Unrealized Investment Gain Loss -28 -106 +73.6%
Accumulated Other Comprehensive Income -8,069 -7,842 -2.9%
Accumulated Translation Adjustment -7,796 -7,984 +2.4%
Additional Paid In Capital 94,469 93,603 +0.9%
Common Stock 481 480 +0.2%
Noncontrolling Interest 299 294 +1.7%
Parent 86,476 88,203 -2.0%
Retained Earnings 114,610 116,725 -1.8%
Treasury Stock Common -115,015 -114,763 -0.2%
Total Liabilities & Equity 208,160 213,396 -2.5%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Depreciation & Amortization 1,687 1,791 -5.8%
Show Business Segments breakouts
Biopharma [Member] · Operating Segments 350 342 +2.3%
Show Consolidation Items breakouts
Corporate Non Segment 80 78 +2.6%
Material Reconciling Items · Acquisition-Related Items [Member] 0 8 -100.0%
Material Reconciling Items · Amortization of Intangible Assets [Member] 1,230 1,359 -9.5%
Material Reconciling Items · Certain Significant Items [Member] 27 3 +800.0%
Asset Write Offs And Asset Impairment Charges 4,406 3,162 +39.3%
Deferred Income Taxes -433 -396 -9.3%
Stock-Based Compensation 225 177 +27.1%
Pension And Other Postretirement Benefit Contributions Net Of Pension And Other Postretirement Benefit Expense -368 454 -181.1%
Other Non-Cash Items -117 -1,805 +93.5%
Net Cash from Operations 5,348 6,721 -20.4%
Investing Activities
Capital Expenditures -845 -917 +7.9%
Payments To Acquire Short Term Investments -4,048 -6,176 +34.5%
Proceeds From Sale Maturity And Collection Of Shortterm Investments 4,723 1,498 +215.3%
Payments For Proceeds From Short Term Investments With Original Maturities Of Three Months Or Less 576 487 +18.3%
Payments To Acquire Marketable Securities -79 -105 +24.8%
Proceeds From Sale Maturity And Collection Of Longterm Investments 591 29 +1937.9%
Proceeds From Sale Of Equity Method Investments 0 3,549 -100.0%
Other Investing Activities -137 15 -1013.3%
Net Cash from Investing -6,146 -1,623 -278.7%
Financing Activities
Repayments Of Short Term Debt 0 -3,452 +100.0%
Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less 101 0 —
Repayments Of Long Term Debt -3,007 0 —
Payments Of Ordinary Dividends -2,445 -2,380 -2.7%
Proceeds From Payments For Other Financing Activities -43 -14 -207.1%
Net Cash from Financing 596 -5,114 +111.7%
Supplemental
Income Taxes Paid 1,017 433 +134.9%
Interest Paid 981 1,394 -29.6%
Interest Paid Received Interest Rate Hedges 45 147 -69.4%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5 -29 +117.2%
Net Change in Cash -196 -45 -335.6%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,197 1,107 +8.1%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key